Announcement • May 14

22nd Century Group, Inc. Highlights FDA Filing of VLN MRTP Renewal Applications for Scientific Review

22nd Century Group, Inc. highlighted that the U.S. Food and Drug Administration has filed for scientific review two Modified Risk Tobacco Product, or MRTP, renewal applications for the Company’s VLN King and VLN Menthol King combusted, filtered cigarettes. The FDA filing marks an important step in the regulatory process for the continued marketing of these products with authorized modified risk claims. VLN King and VLN Menthol King were originally granted MRTP exposure modification orders by the FDA in December 2021, making them the first combusted cigarettes ever authorized as MRTPs. Those orders are set to expire in December 2026 unless renewed, and the current review process is intended to support continued modified risk marketing status beyond that date. Under the existing FDA orders, 22nd Century is authorized to market VLN King and VLN Menthol King with specific reduced-exposure nicotine claims, including “95% less nicotine,” “Helps reduce your nicotine consumption,” and “…Greatly reduces your nicotine consumption,” provided those claims are accompanied by the statement “Helps you smoke less.” The Company believes the continued review of these products is strategically important because VLN remains a uniquely differentiated product platform within the combustible tobacco category. In connection with the renewal process, the FDA has begun releasing redacted application materials for public access and opened a docket for public comment, enabling stakeholders to submit data and feedback as part of the scientific review. 22nd Century believes this process further underscores the rigor of the FDA’s modified risk framework and the significance of maintaining a robust evidence base for its VLN franchise. In its original MRTP review, the FDA found that nicotine levels in the tobacco and mainstream smoke of VLN cigarettes are at least 95% lower than the majority of marketed and market-leading conventional cigarette brands. The agency also stated that consumers who exclusively use cigarettes with the same or similarly reduced nicotine content as VLN cigarettes could reduce their nicotine exposure by approximately 95%, and that use of these products is reasonably likely to reduce nicotine dependence. 22nd Century previously announced that its renewal submission was supported by additional marketplace data, including a 2024 study involving more than 400 participants, which the Company said demonstrated a 40% reduction in daily cigarette consumption over 12 weeks among smokers using VLN cigarettes. The Company believes this data strengthens the long-term commercial and regulatory case for the VLN platform, although the outcome and timing of the FDA’s renewal review remain subject to the agency’s independent evaluation. This release does not announce renewal approval, and no assurance can be given regarding the outcome of the FDA’s review.

22nd Century Group, Inc. Stock Price

XXII Share Price Performance

XXII Community Narratives

Low Nicotine Mandate And Harm Reduction Trend Will Reshape This Tobacco Business

Low Nicotine Mandate And Harm Reduction Trend Will Reshape This Tobacco Business

Trending Discussion

Recently Updated Narratives

Low Nicotine Mandate And Harm Reduction Trend Will Reshape This Tobacco Business

Snowflake Analysis

22nd Century Group, Inc. Key Details

About XXII

Recent XXII News & Updates

22nd Century Group Inc Launches Pinnacle Pure At Major U S Retailers

22nd Century Group, Inc. Highlights FDA Filing of VLN MRTP Renewal Applications for Scientific Review

22nd Century Group, Inc. to Report Q1, 2026 Results on May 07, 2026

Recent updates

22nd Century Group, Inc. Competitors

Real Good Food Company

IP Strategy Holdings

Splash Beverage Group

Innovation Beverage Group